N.J. senator suggests bussing commuters off gridlocked I-80 after 3rd sinkhole
Commuters endured bumper to bumper traffic on detours Thursday during the first full day that all lanes of Interstate 80 were ...
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
PEMGARDA (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 ...
Trump moves to close gaps in San Diego border fence, but environmental concerns linger
The border wall system running through San Diego County has been one of the most fortified stretches in the southwest for ...
LIVE
President Trump to sign executive order dramatically shrinking Department of Education: Live updates
President Trump to sign executive order dramatically shrinking Department of Education: Live updates - President set to order Education Secretary Linda McMahon to begin dismantling federal agency and ...
Railway Gazette International17h
Amtrak CEO Gardner leaves as operator pushes back against Musk’s privatisation drive
USA: Amtrak CEO Stephen Gardner announced on March 19 that he was stepping down from the national passenger operator with ...
Doctors Told Him He Was Going to Die. Then A.I. Saved His Life.
The first time Dr. Fajgenbaum repurposed a drug, it was in an attempt to save his own life. At 25, while in medical school, ...
Trains on MSN7hOpinion
CEO's dismissal signals the beginning of the end for Amtrak: Analysis
Nothing good will come from Wednesday’s dismissal of Amtrak CEO Stephen Gardner, who was pushed out as part of the White ...
City of Hope Opens Trial to Test Bone Medication for Early Type 1 Diabetes Treatment
City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States and a top ...
Novartis4h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...